Vilius Rudaitis

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin et al. · Annals of Oncology · 2019 · 786 citations · Full text

Antitumor Activity, Oncology, Medicine +6

Cancer Risks Associated With Germline<i>PALB2</i>Pathogenic Variants: An International Study of 524 Families

Xin Yang, Goska Leslie, Alicja Doroszuk et al. · Journal of Clinical Oncology · 2019 · 393 citations · Full text

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.

Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin et al. · Journal of Clinical Oncology · 2018 · 61 citations

Cancer Management, Gynecology, Pathology +19

Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.

Ursula A. Matulonis, Roni Shapira, Alessandro D. Santin et al. · Journal of Clinical Oncology · 2020 · 44 citations

Final Results, Prognostic Biomarkers, Pd-l1 Expression +13

Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania

Ramūnas Janavičius, Vilius Rudaitis, Ugnius Mickys et al. · Cancer Genetics · 2014 · 30 citations

Somatic Variant, Genetic Disorder, Medicine +5